Welcome to our dedicated page for Bolt Biotherapeutics SEC filings (Ticker: BOLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the U.S. Securities and Exchange Commission’s EDGAR system. As a clinical-stage biopharmaceutical company developing immunotherapies for cancer, Bolt Biotherapeutics uses its SEC filings to report financial results, material corporate events, and updates on its research and development activities.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand the company’s research and development spending, collaboration revenue from its partnerships, and detailed risk factors related to advancing product candidates such as BDC-3042 and BDC-4182. These filings also describe the Boltbody ISAC platform, the status of clinical and preclinical programs, and the company’s cash position and operating runway as disclosed in its financial statements.
Current reports on Form 8-K provide timely information about specific events, such as announcements of quarterly financial results, restructuring plans that include workforce reductions, and updates on ongoing clinical studies. For example, Bolt Biotherapeutics has used Form 8-K to furnish press releases describing changes to the BDC-4182 Phase 1 protocol and the expected timing of initial clinical data, as well as to outline cost-reduction measures intended to preserve cash.
Through this page, users can also access insider transaction reports on Form 4 and other relevant filings, when available, to monitor equity transactions by officers and directors. Stock Titan’s interface is designed to pair these documents with AI-powered summaries that explain key points in accessible language, helping readers quickly interpret complex disclosures without replacing the underlying source documents. By reviewing Bolt Biotherapeutics’ SEC filings alongside news and market data, investors can form a more complete picture of the company’s financial condition, pipeline progress, and regulatory communications.
A director of Bolt Biotherapeutics, Inc. reported cancelling previously granted director stock options and receiving new options with lower exercise prices.
On December 12, 2025, the director received new options to buy 2,500, 849, 1,000 and 1,100 shares of common stock at an exercise price of $5.44 per share, with expiration dates between September 2, 2034 and May 26, 2035. In each case, options with higher exercise prices ranging from $6.40 to $13.596 for the same number of shares and similar expiration dates were cancelled in exchange for the new options, some of which are fully vested and others subject to monthly or time-based vesting and full vesting upon a change in control.
Bolt Biotherapeutics, Inc. director reported stock option transactions dated
New director stock options with exercise prices such as
Bolt Biotherapeutics, Inc. reported that one of its directors entered into several option transactions on 12/12/2025. The director cancelled previously granted stock options with higher exercise prices and received new director stock options with an exercise price of $5.44 per share for the same numbers of underlying common shares.
One option grant for 2,500 shares expiring in 2032 vests in equal monthly installments from December 14, 2022 until the third anniversary of that date, while other grants reported are already fully vested and exercisable. Another 1,100-share option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, and certain of these options vest in full upon a change in control of the company.
A director of Bolt Biotherapeutics, Inc. reported multiple option transactions dated December 12, 2025 involving director stock options on Bolt common stock. The director canceled several existing stock options and received new director stock options over the same numbers of shares, with each exchange recorded as a disposal and a corresponding acquisition.
In each case, the existing option was canceled in exchange for a new option with a lower exercise price of $5.44. One new option covering 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the director’s continuous service, and will vest in full upon a change in control of Bolt Biotherapeutics.
Bolt Biotherapeutics, Inc. director reported multiple stock option changes dated December 12, 2025. The reporting person agreed to cancellation of existing director stock options that had higher exercise prices such as $180.2, $60.6, $39.8, $32.6, $15.364 and $6.4 in exchange for new options having a lower exercise price of $5.44 per share. These new options cover blocks of common stock, including 1,393 and 1,810 shares. One new option for 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, and will vest in full upon a change in control of the company.
Bolt Biotherapeutics reported insider equity activity involving its Senior VP, Finance and PAO, with an earliest transaction date of 12/12/2025. The filing covers a series of employee stock options on common stock.
The executive agreed to cancel multiple existing stock options granted between 2020 and 2025 in exchange for new employee stock options with a lower exercise price of $5.44 per share, in blocks such as 1,236, 375, 600, 2,199, 6,699, 1,589, 2,499, 4,499 and 11,299 shares. Some replacement options vest in equal monthly installments of 1/36th of the shares, so long as the executive continues providing services, with vesting schedules beginning after dates including January 1, 2023, January 1, 2024, July 15, 2024 and January 1, 2025. At least one option is already fully vested and exercisable.
Bolt Biotherapeutics, Inc. reported that its Chief Operating Officer adjusted multiple employee stock options on 12/12/2025. Existing options with higher exercise prices were cancelled, and new employee stock options with a $5.44 exercise price and the same share amounts and expiration dates were granted in exchange.
One of the new options is fully vested and exercisable. Several other new options vest in equal 1/36th installments each month after specified dates in 2023, 2024 and 2025, for so long as the reporting person continuously provides services to the company.
Bolt Biotherapeutics reported changes to a senior insider’s equity compensation on December 12, 2025. The reporting person is a director who also serves as President, CEO and CFO, and the transactions involve employee stock options to purchase common stock.
Several existing stock option grants with higher exercise prices were cancelled in exchange for new employee stock options with an exercise price of $5.44 per share. One of the options is fully vested and exercisable, while multiple new options vest in 36 monthly installments as long as the reporting person continues providing services, with vesting schedules starting from dates such as January 1, 2023, January 1, 2024, July 15, 2024, and January 1, 2025.
Bolt Biotherapeutics filed its Q3 2025 10‑Q, reporting collaboration revenue of $2.169 million and a quarterly net loss of $7.144 million (basic and diluted net loss per share $3.72). Operating expenses were $9.872 million, reflecting lower R&D and G&A versus the prior year. Other income was $0.559 million, aided by interest.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $38.8 million, with total assets of $65.053 million and stockholders’ equity of $32.101 million. Management states these resources may be sufficient to fund operations into 2027, yet concluded there is substantial doubt about continuing as a going concern within one year of issuance, given dependence on collaboration income and additional financing.
The company implemented cost controls, including subleasing facilities and prior workforce reductions, and on October 1, 2025 announced a new restructuring to cut about 20 employees (~50%), with estimated charges of $1.5–$2.0 million to be recorded in Q4 2025. A 1‑for‑20 reverse stock split was effected on June 6, 2025. Shares outstanding were 1,919,441 as of November 5, 2025.
Bolt Biotherapeutics (BOLT) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025 and a corporate update. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company states the information is furnished, not filed, and therefore is not subject to Section 18 liability under the Exchange Act nor automatically incorporated into other SEC filings.
FAQ
What is the current stock price of Bolt Biotherapeutics (BOLT)?
What is the market cap of Bolt Biotherapeutics (BOLT)?
